Format

Send to

Choose Destination
Pathol Res Pract. 2018 Jun;214(6):907-913. doi: 10.1016/j.prp.2018.03.014. Epub 2018 Mar 15.

COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma.

Author information

1
Oral Medicine Department, Sírio-Libanês Hospital, Dona Adma Jafet Street, 115, Bela Vista, São Paulo, SP, 01308-050, Brazil.
2
Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, 31270-901, Pampulha, Belo Horizonte, MG, Brazil.
3
Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Av. Limeira, 901, CEP 13.414-903 Piracicaba, São Paulo, Brazil.
4
Department of Pathology, A. C. Camargo Cancer Center, Professor Antônio Prudente Street, 211, ZipCode 01509-010, São Paulo, Brazil.
5
Laboratory of Molecular Biology, Sírio-Libanês Hospital, Dona Adma Jafet Street, 115, Bela Vista, São Paulo, SP, 01308-050, Brazil.
6
Oral Medicine Department, Sírio-Libanês Hospital, Dona Adma Jafet Street, 115, Bela Vista, São Paulo, SP, 01308-050, Brazil. Electronic address: eduardofregnani@me.com.

Abstract

Ameloblastoma is a locally aggressive neoplasm with a poorly understood pathogenesis. Therefore, the aim of this study is to investigate whether COX-2 expression is associated with ameloblastoma microvascular density (MVD) and with tumor aggressiveness. Sixty-three cases of primary ameloblastomas arranged in tissue microarray were submitted to immunohistochemistry against cyclooxigenase-2 (COX-2) and CD34. Clinicopathological parameters regarding sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic features, vestibular/lingual and basal cortical disruption and follow-up data were obtained from patients' medical records and correlated with the proteins expression. The results on BRAF-V600E expression were obtained from our previous study and correlated with COX-2 and CD34 expressions. Log-rank univariate analysis and multivariate Cox regression model were done to investigate the prognostic potential of the molecular markers. Twenty-eight cases (44.4%) exhibited cytoplasmic positivity for COX-2, predominantly in the columnar peripheral cells, with a mean MVD of 2.2 vessels/mm2. COX-2 was significantly associated with recurrences (p < 0.001) and BRAF-V600E expression (p < 0.001), whereas lower MVD was associated with the use of conservative therapy (p = 0.004). Using univariate and multivariate analyses, COX-2 was significantly associated with a lower 5-year disease-free survival (DFS) rate (p < 0.001 and p = 0.012, respectively), but not with a higher MVD (p = 0.68). In conclusion, COX-2 expression in ameloblastomas is not associated with MVD, but it is significantly associated with recurrences and with a lower DFS.

KEYWORDS:

Ameloblastoma; CD34; COX-2; Cyclooxigenase-2; Odontogenic tumors

PMID:
29559247
DOI:
10.1016/j.prp.2018.03.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center